sign in sign up
<<
Home , Naloxazone, Org 6582, Pempidine, Piribedil, Pridefine, Salbutamol

INDEX

ABTX,426 Aggression (cont'd) , 263 aggression, 198 methylxanthine, 263 electroconvulsive shock, 386 , 196 hypothalamic, aggression, 187 morphine withdrawal, 251-252 morphine withdrawal, 252 pain-induced, 189, 192-193 synthesis, electroconvulsive shock, 398- pathological, 254 399 , 255 ACTH, see Adrenocorticotropic hormone predatory, 203-204, 226 receptors prevalent aggressive behavior pattern, beta, electroconvulsive shock, 391-393 267 Adrenocorticotropic hormone psychopharmacology, 183-277 analogs, 545 resident-intruder, 201-202 memory, 543-546 seizure, 198-199 Affective states, conditioning, 26-36 , 187 Aggression sexual, 233-234 acetylcholine, 198 status-related, 199-20 I hypothalamic, 187 ,255-261 affective, 194 , 263 aggression, 235-245 autoaggression, 228 animal,235-241 brain lesion-induced, 195 determinants, 238 brain stimulation-evoked, 194-195 dose-effect relationship, 238 brain tumor, 194 homicide, 241-245 cannabis, 255-261 mechanism, 245 , 196 , 239 , 263 violence, 241, 242 "code," 187 Alpha-methyl-p-, treatment, 204-205 , 339 frustration-induced, 193 , , 611 , 196, 252-263 Alzheimer's dementia, 549 interspecies, 203 model,452 intraspecies, 203 isolation-induced, 188-189 assay, 623 lysergic acid diethylamide, 253-254 carbohydrate ingestion, 133, 135 maternal, 202-203 predatory aggression, 226 , 254-255 structure, 610 633 634 INDEX

Amoxapine,611 Anticonvulsant Amphetamine aggression, 232-233 aggression, 263 tolerance to, 24-26 clinical data, 274-275 drugs determinants of effect, 266-271 aggression, 223-228 dose-related response, 267 assay, 623 drug administration, 271 binding sites, 617 drug antagonism, 272 vs. electroconvulsive therapy, 376 rage response, 266 food intake, 133 anorexic effect, 21 binding, 619 antiaggressive effect, 272 second-generation, 609-631 drug antagonism, 272 behavioral assays, 619-625 efficacy, 275 mechanism of action, 612-616 conditioned place preference, 33 neurological assays, 616-619 conditioned taste aversion, 28 serotonin antagonism, 622 release feeding behavior, 152 AI0 neuron activity, 338 feeding pattern, 142 aggression, 269 vs. , 152 attack behavior, 269 food intake, 129 food intake, 130 6-hydroxydopamine, 196 morphine withdrawal, 252 locomotor activity, 169 blockade, 447 mechanism of action, 74-75 stereotypy, 577 motor activity, 71 Appetitive behavior, 600-602 nicotine blockade, 447 Arcuate nucleus, 13 orexic and anorexic effect, 169-171 , 386 quantitative effects, conceptualization, catalepsy, 386 170 discrimination, 447 reverse tolerance, 18 Arginine vasopressin, 540 social status-dependent effect, 269 Attention deficit disorder stereotypy, 577 diagnosis, 68 stress response, 8 differential diagnosis, 69 substance P blockade, 552 with hyperactivity, 64, 68-74 Tourette's syndrome, 96 neurochemistry, 75-84 Amygdala, 482 phenylethylamine,83 , 426 Tourette's syndrome, 96 generalization with nicotine, 439 treatment, 74 Analgesia (see also Pain) Attentional dysfunction, 61, 70 amygdala, 482 endogenous systems, 485-495 (see also food intake, 129 ) , 15 footshock-induced, 485, 490-493 Autoreceptor, 337 , 478-484 nerve terminal, 337 stimulation-produced, 480 supersensitivity, 355 stress-induced, 7, 23 Avoidance response, 577 Androgens, 135 Azepindole,611 Anesthetic , 502 Angel dust, see Phencyclidine Angiotensin II, 550 aggression, 213-214, 216-217 Anorexia, 161-168 food intake, 134 Anorexia nervosa, 136 Behavior Antiandrogenic agents, 233-234 aggression, 183-277 INDEX 635

Behavior (coot'd) feeding, 123-181 aggression, 214-215 predatory, 197 food intake, 133 Benzedrine, 84, 86 nicotine, 442 satiation, 141 antiaggressive effect, 220 Chlorimipramine, 226 food intake, 133, 134 , 426 rage reactions associated with, 222 nicotine blockade, 447 receptors, 220 p-Chlorophenylalanine,379 taming action, 213 Beta-adrenergic blockers, 211-213 aggression, 206-208, 210 Beta-funaltrexamine, 500 amphetamine aggression, 272 Bicuculline,381 food intake, 133, 134 Blood pressure, 15 Cholecystokinin, 550-551 Body temperature, 9-12 food intake, 130,551 Bombesin, 130 memory, 551 Brain tumor, 194 Cigarette smoking, 451 Bulbocapnine Circadian rhythm, 8 cardiovascular effects, 15 Clonidine mechanism of action, 15 aggression, 196 attention deficit disorder with assay, 624 hyperactivity, 74 mechanism of action, 611 dosage, 101, 102 structure, 610 food intake, 135 as a training drug, 621 haloperiodol with, 102 Butyrophenones vs. , Tourette's syndrome, 101 aggression, 205, 210 onset of action, 10 1 catalepsy, 578 , 102 Bypass surgery, intestinal, 127 Tourette's syndrome, 97, 101-102 withdrawal symptoms, 98 Clothiapine,211 aggression, 275 food intake, 135 aggression, 211 Calcitonin, 130 food intake, 134 Calcium, 400-401 Cocaine , 196 aggression, 263 Cannabis, 255-261; see also food intake, 131 Tetrahydrocannabinol reverse tolerance, 18 , 426 Conditioned drug effects, 2 Cardiovascular system, 15-16 cardiovascular, 15-16 , 611 drug self-administration, 37 Catalepsy, 578 paradoxical conditioning, 9 , see Conditioned place preference, 28 , 132 amphetamine-induced, 33 Central nervous system cocaine-induced, 33 dopamine receptors, 338 development, 33 nicotinic receptor, 454-457 Conditioned response, 2 Cerebral vascular disorders, 502 Conditioned stimulus, 1 CGS 8216, 132 Conditioned taste aversion, 27-29 Chemotherapy, 36-37 loss of, 32 Childhood psychiatric disorders, 59-121 , 31 Chloralose, 134 nicotine, 435-436 636 INDEX

Conditioning Dopamine (cont'd) drug effects, 2 , 267 evidence, 4 amphetamine-stimulated, 19 optimal conditions, 5-6 appetitive behavior, 600-602 tests, 3-4 attention disorder deficit with Contingent tolerance, 21 hyperactivity, 75 , 443 cerebral cortex, 330 , 259 depletion, 578 Cyclic AMP, 399-400 electroconvulsive shock, 380-382 intracranial self-stimulation, 579 anorexia nervosa, 136 mesocortical system, 330-332 food intake, 134, 136 mesolimbic system, 330-332 , 233, 234 midbrain systems, 330-332 , 426 A9 vs. A10, 332-334 generalization with nicotine, 439 electrophysiological identification, 334-337 d-Ala2-d-Leu5- (DADLE), 501 neuron regulation, 337-355 Danitracen, 611 nigrostriatal system, 330 De Lange syndrome, 266 opiate reward, 498 Depressive illness, 375 reciprocal action with serotonin, 146 , 623 synthesis, 390 Desmethylimipramine, 352 Dopamine receptors Dextroamphetami~e CNS, 338 AI0 neuron activity, 338 D-2 subtype, 338 -methyl-p-tyrosine, 339 Drug(s) vs. fenfluramine, 146 of abuse, 235-277 haloperidol antagonism, 344 aggression, 204-235 learning disability, 90 , see Antidepressant mechanism of action, 70 drugs rebound effect, 72 food intake, 126-136 , 379 pediatric , 65-67 Diethylpropion, 146 tranquilizers, see Tranquilizers Dimethyl-phenylpiperazinium, 426 treatment, 40 Diphenylhydantoin, 233 Drug effects L-dopa conditioned, 2 AIO neuron activity, 338 multiple, 6-7 morphine withdrawal, 252 observed,2 Dopamine Drug self-administration, 37-40, 423 A8 neurons, 331 conditioned drug effects, 37 A9 neurons, 331, 332-334 Drug tolerance, 354 A10 neurons, 331 conditioning factors in, 18-26 vs. A9, 332-334 Dyslexia chronic neuroleptic administration, neuropsychological syndromes in, 85 352 piracetam, 92 effect of agonists, 338-348 GABA, 351, 355-358 Electroconvulsive shock isoproterenol, 359 acetylcholine, 386 , 359 vs. antidepressant drugs, 376 , 359 beta-, 391-393 serotonin, 358-359 clonidine-induced neuroendocrine substance P, 360 response, 401 , 359 dopamine, 380-382 INDEX 637

Electroconvulsive shock (com'd) (com'd) GABA, 383-386 predatory aggression, 226 haloperidol-induced catalepsy, 383 structure, 610 5-hydroxytryptamine, 377-380, 402 Flurothyl,377 naloxone, 386-387 Flutamide, 233 neurotensin, 400 Food intake , 382-383 alteration, 139 opioids, 386-387 carbohydrates, 144 substance P, 400 control,125-126 Electroconvulsive therapy drugs, 126-136 calcium levels, serum, 400-401 enhancement, 132-136 depressive illness, 375 fat, 144 mechanism ofaction, 375-408 vs. feeding behavior, 137 Endorphins, see Opioids naloxone, 155-158 Enkephalin, 480 , 159 Enterogastrone, 130 nicotine, 450 protein, 144 blood pressure, 15 psychopharmacology, 123-182 cardiovascular effects, 15 satiation, 141 food intake, 129 serotonin, 149-150 Estradiol, 259 serotonin synthesis, 144-145 Estrogens, 130 suppression, 128-132, 136-137 Ethanol (see also Alcohol) , 150 anticonvulsant effects, 24 Formamidines, 135 hypothermia, 11 Gamma-aminobutyric acid (GABA), 232 tolerance, 16, 20 AIO dopamine neurons, 351, 355-358 Ethyl-p-carboline-3-carboxylate, electroconvulsive shock, 383-386 220 synthesis, 393-395 Euphoria,579-580 Gates Diagnostic Reading Test, 90 Extinction, 3 Glucose, 129 Glutamic acid, 351 Feeding behavior Glutamic acid decarboxylase, 396 amphetamine, 152 Glycerol, 129 control, models, 171-173 Gray Oral Reading Test, 85 fenfluramine, 152 vs. food intake, 137 Hallucinogens serotonin manipulation, 145-155 aggression, 196, 252-263 structure, 139-142 Haloperidol Feeding patterns, 160-161 aggression, 208, 210 Fenfluramine amphetamine aggression, 272 vs. amphetamine, 152 amphetamine-induced conditioned place anorexic activity preference, 33 context-dependency,l71 clonidine with, 102 mechanism, 147, 149 vs. clonidine, 101 feeding behavior, 152 dextroamphetamine, 344 feeding patterns, 142 dosage, 101 food intake, 130 with methylphenidate, 100 vs. other anorexic agents, 146 onset of action, 101 satiation, 142 side effects, 100 , 611 tardive dyskinesia, 100-101 Fluoxetine tolerance, 354 mechanism of action, 611 Tourette's syndrome, 95, 99-100 638 INDEX

Heart rate Insulin, 135 conditioned, 16 Insulin receptor, 13 deceleration, 16 Insulin secretion, 14 , 426 cephalic phase, 14 Homovanillic acid, 80 conditioning of changes, 12-15 Horseradish peroxidase, 331 Intracranial self-stimulation Hydroxycitrate, 129 dopamine, 579 6-Hydroxydopamine, 331 nicotine, 448-449 amphetamine, 196 thresholds, measurement, 586 attack behavior, 268 Iowa Test of Basic Skills, 90 irritability, 196 5-Hydroxyindoleacetic acid, 96 assay, 621 5-Hydroxytryptamine mechanism, 611 electroconvulsive shock, 377-380, 402 structure, 610 head-twitch behavior, 388 Isoproterenol receptor; 388 AI0 dopamine neurons, 359 synthesis, 387 food intake, 132 5-Hydroxytryptophan electroconvulsive shock, 378 Killer weed, see Phencyclidine feeding pattern, 142 Korsakoff's syndrome, 540 food intake, 130 Hyperactivity (see also Attention deficit Learned helplessness, 619 disorder, with hyperactivity) Learning; see also Memory animal models, 76-79 defined,533 diagnosis, 68 Learning disability, 64, 84-93 (see also 3-methoxy-4-hydroxyphenylethylene Learning disorder) glycol, 80-82 dextroamphetamine, 90 prevalence, 68 long-term therapy, 91-92 vanillylmandelic acid, 83 methylphenidate, 87 Hyperkinetic child, 64 (see also Learning disorder Hyperactivity) diagnosis, 84-85 Hyperphagia, 127 Lesch-Nyhan syndrome, 266, 540 , essential, opioids, 502 Lipid synthesis, 128 Hyperthermia, 10 , 130 Hypoglycemia, 14 Hypophagia, 127 aggression, 228-232 Hypothalamus, 194 antiaggressive effect Hypothermia clinical evidence, 231 ethanol, 11 mechanism, 230 impromidine-induced, 387 conditioned taste aversion, 230 , 12 pediatric use, 232 predatory behavior, 230 leI 154, 129,502 Lithium chloride , 352 anorexic activity, 162-168 conditioned taste aversion, 28 antiaggressive effects, 223, 224 , 426 hyperactivity, 228 nicotine binding, 441 increased aggressiveness, 226 Locomotor activity vs. placebo, 91 amphetamine, 169 structure, 610 morphine, 19 Immune response, 16-17 ,611 Impromidine, 387 LSD, see Lysergic acid diethylamide INDEX 639

Lysergic acid diethylamide Methylphenidate (cont'd) aggression, 196, 253-254, 261 vs. placebo, 91 predatory killing, 254 Tourette's syndrome, 96 vasopressin, 535 Methylxanthine, 263 amnesia, 540 avoidance task, 536 amphetamine aggression, 272 discrimination, 447 food intake, 134 mechanism of action, 611 5-hydroxytryptamine-mediated behavior, predatory aggression, 226 379 Marihuana, see Cannabis, Tetrahydrocannabinol assay, 621 serotonin antagonism, 622 vs. fenfluramine, 146 structure, 610 food intake, 129, 130 , 447 Mecamyline, 426 Midbrain nicotine discriminative effects, 447 dopamine systems, 330-332 nicotine-induced conditioned taste dopamine-containing neurons, 329, aversion, 436 332-334 Medroxyprogesterone acetate, 234 electrophysiological identification, Memory 334-337 defined,533 regulation, 337-355 James-Lange theory, 559 Milenperone, 211 neuropeptides, 531-573 Minimal brain dysfunction, 64 adrenocorticotropic hormone, 543- ,211 546 Monoamine oxidase inhibitors, 223 neurotensin, 549-550 antiaggressive effects, 225 opioids, 546-548 assay, 623 , 542-543 Morphine somatostatin, 548-549 aggression, 196, 245-253 substance P, 552 body temperature, 10 vasopressin, 535-542 cardiovascular effects, 15 Meprobamate, 133, 134 discrimination, 447 Mescaline, 196, 254-255 heart rate, 15 Metenkephalin, 248 hyperthermia, 10 electroconvulsive shock, 397 locomotor activity, 19 3-Methoxy-4-hydroxyphenylethylene glycol reverse tolerance, 18 hyperactivity, 80-82 stress-induced analgesia, 7 Tourette's syndrome, 97 tolerance, 23 5-Methoxy-N,N-dimethyltryptamine, 254 withdrawal, 30, 251 Methylphenidate theory, 168 AI0 neuron activity, 338 , 131 aggression, 263, 274, 275 antiaggressive effect, 275 , 38 controlled trials, 90 , 502 dosage, 87 Naloxone efficacy, 90 aggression, 247 half-life, 87 cigarette smoking, 451 haloperidol, 100 conditioned taste aversion, 31 learning disability, 87 electroconvulsive shock, 386 mechanism of action, 70 feeding pattern, 142, 160-161 morphine withdrawal, 252 food intake, 131, 155-158,249 640 INDEX

Naloxone (conl'd) Noradrenaline, see Norepinephrine social interaction, 248 Norepinephrine stimulation-produced analgesia, 480 attention disorder deficit with stress-induced analgesia, 7 hyperactivity syndrome, 75 Naltrexone electroconvulsive shock, 382-383, 390- aggression, 248 393 feeding pattern, 142 food inuke, 129 foodinuke, 159,249 morphine withdrawal, 252 Neimarck Memory Test, 93 , 610 Neuroleptic drugs, 575-607 Nucleus raphe magnus, 481 hypothesis, 580 Nucleus reticularis gigantocellularis, 481 anticipation-invigoration, 595 apomorphine stereotypy, 577 Observed drug effects, 2 appetitive task performance, 577 Obesity, 153-154 catalepsy, 578 Operant behavior, 598-600 passive avoidance response, 577 , 467-529 response-reinforcement matching, 589- cardiovascular effects, 499-502 592 defined,467 Neuropeptides mechanism of action, 478, 479 blood-brain barrier permeability, 556- vs. opioids, 467 557 pain transmission, 478-484 memory, 531-573 receptors, 500-501 Neurotensin reward, 495-499 electroconvulsive shock, 400 Opioids memory, 549-550 electroconvulsive shock, 386-387 sites, 549 memory and learning, 546-548 Nicotine, 421-457 (see also Cigarette vs. opiates, 467 smoking) , 130 analogs, 439, 442 , 502 as an aversive stimulus, 434-437 , 223 as a negative reinforcer, 435 Oxytocin, 542-543 as a punisher, 434-435 chlordiazepoxide, 442 Pain CNS receptor, 454-457 opiates, 469-495 cocaine generalization, 443 transmission conditioned taste aversion, 435-436 afferent pathways, 471-478 cue, origin opiates, 478-484 discriminative stimulus effects, 437-448 Paradoxical conditioning, 9 blockade, 447 Peace pill, see Phencyclidine characteristics, 445 , 96 chlorisondamine, 447 Pempidine, 426 , 447 Pentobarbital, 12 drug generalized with, defined, 439 Pentobarbitone, 447 food inuke, 450 Phencyclidine intracranial self-stimulation, 448-449 aggression, 196, 255 picrotoxin, 442 discrimination, 447 as a positive reinforcer, 429-432 , 610 self-administration, 430-433, 452 (see also specific agents) , 622 aggression, 205, 210 catalepsy, 578 food intake, 130 weight gain, 133 mechanism of action, 611 , 272 structure,6lO , 383 INDEX 641

Phenylethylamine Rauwolscine, 359 attention disorder deficit with activity, Reinforcement, 450 83 Ro 15-1788 food intake, 132 antagonism, 220 Phenylpropanolamine, 132 diazepam antagonism, 220 Picrotoxin, 442 Rocket fuel, see Phencyclidine aggression, 208 , 132 amphetamine aggression, 272 Satietin, 129 cardiac effects, 103 Satiation, 141 chemical structure, 103 SCH 12, 679 clinical trials, 103 , 447 dosage, 103 Seizure efficacy, 103 aggression, 198-199 euphoria, 579-580 bicuculline, 381 mechanism of action, 103 functional changes following, 377- pediatric dosage, 103 387 vs. placebo, 103 Senile dementia, 92 reinforcement-suppressing effect, 579 Serotonin side effects, 103 AI0 dopamine neurons, 358-359 Tourette's syndrome, 102-103 aggression, 187 , 212 antagonism, 622 Piperoxan, 359 attention disorder deficit with , 353 hyperactivity syndrome, 75 Piracetam, 92-93 dietary self-selection, 151-152 dyslexia, 92 drug-induced aggression, 196 vs. placebo, 92-93 feeding behavior, 145-155 senile dementia, 92 food intake, 130, 149-150 , 130 morphine withdrawal, 252 , 622 reciprocal action with dopamine, 145 amphetamine aggression, 272 synthesis, 144-145 dopamine neurons, 352 Serotonin syndrome, 623 Pridefine,611 Somatostatin Progabide, 611 Alzheimer's dementia, 549 food intake, 130 aggression, 211 memory, 548-549 food intake, 134 Spinothalamic nociceptive neuron, 473- 478 aggression, 211, 212 , 142 amphetamine aggression, 272 , 208 Prostaglandins Stereotypy food intake, 131 amphetamine, 577 precursors, 131 apomorphine, 577 Psychotherapy, 99 (3)-Pyridyl-methylpyrollodine, 439 clinical effects, 70-74 in pediatrics, 70-74 Quinine, 162-168 Stress response, 7 Quinuclidinylbenzylate, 399 Strychnine, 385 Substance K, 360 discrimination, 447 Substance P, 551-553 food intake, 130 AIO dopamine neurons, 360-362 seizure threshold, 385 amphetamine blockade, 552 642 INDEX

Substance P (com'd) Tourette's syndrome (com'd) electroconvulsive shock, 400, 552 methylphenidate, 96 memory, 552 motor coordination, 94 , 352 multiple handicaps, 105-106 neurochemical research, 95-98 , 611 pemoline, 96 Tardive dyskinesia, 100-10 1 pimozide, 102-103 Taste aversion, 27-29 psychotherapy, 99 Temperature, body, see Body temperature Tranquilizers, 133 , 623 Tetrahydrocannabinol predatory aggression, 226 aggression, 255-261 structure, 610 effects, 257 antiaggressive effect mechanism of action, 611 estradiol treatment, 259 serotonin antagonism, 622 mechanism, 261 structure, 610 morphine withdrawal, 259 temperature, 259 feeding pattern, 142 tryptophan hydroxylase, 259 food intake, 130 corticosterone, 259 Tryptophan hydroxylase, 259 dose-related response, 257 Tubocurarine, 426 food intake, 131 Testosterone, 239 U1tradian rhythm, 8 , 210 Unconditioned response, 2 THIP, 131 Unconditioned stimulus, 1 Threochlorocitrate, 129 Thyrotropin-releasing hormone, 130 Vanillylmandelic acid, 83 , 248 Vasopressin, 535-542 food intake, 135 learning and memory, 535-542 Tolerance (see also Tolerance under physiological action, 535 specific drugs) contingent, 21 mechanism of action, 611 drug, see Drug tolerance serotonin antagonism, 622 Tourette's syndrome, 93-106, 266 amphetamine, 96 WA 355-BS, 134 attention disorder deficit with Wide Range Achievement Test, 85, 89, 91, hyperactivity, 95 93 choice of medication, 104 clonidine, 97, 101-102 Xylamidine, 150 CSF 5-hydroxyindoleacetic acid, 96 diagnosis, 99 Yohimbine EEG abnormality, 94 A10 dopamine neurons, 359 etiology, 94 food intake, 135 genetic aspects, 95 haloperidol, 95, 99-100 incidence, 95 mechanism of action, 611 3-methoxy-4-hydroxyphenylethylene, serotonin antagonism, 622 97 ,611